Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
Authors
Keywords
Anti-tumor activity, Patient-derived xenografts, TGF-β, Galunisertib, Gene expression
Journal
CELLULAR ONCOLOGY
Volume 38, Issue 2, Pages 131-144
Publisher
Springer Nature
Online
2015-01-08
DOI
10.1007/s13402-014-0210-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The cancer genome: from structure to function
- (2014) Ad Geurts van Kessel CELLULAR ONCOLOGY
- Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
- (2013) Francesco Dituri et al. PLoS One
- Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response
- (2013) Matthew David Hale et al. CELLULAR ONCOLOGY
- MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
- (2012) Sidong Huang et al. CELL
- Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer
- (2012) S. Julien et al. CLINICAL CANCER RESEARCH
- The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men
- (2012) S. Kopetz et al. CLINICAL CANCER RESEARCH
- Abstract C201: The combination of the small molecule TGF R1 inhibitor LY2157299 monohydrate with CCNU substantially blocks SMAD phosphorylation and significantly suppresses human glioblastoma xenograft growth.
- (2012) S. Parsons et al. MOLECULAR CANCER THERAPEUTICS
- Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
- (2012) Mallika Singh et al. NATURE BIOTECHNOLOGY
- Targeting the TGFβ signalling pathway in disease
- (2012) Rosemary J. Akhurst et al. NATURE REVIEWS DRUG DISCOVERY
- Jetset: selecting the optimal microarray probe set to represent a gene
- (2011) Qiyuan Li et al. BMC BIOINFORMATICS
- Outgrowth of Drug-Resistant Carcinomas Expressing Markers of Tumor Aggression after Long-term T RI/II Kinase Inhibition with LY2109761
- (2011) E. C. Connolly et al. CANCER RESEARCH
- Role of Smads in TGFβ signaling
- (2011) Carl-Henrik Heldin et al. CELL AND TISSUE RESEARCH
- Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
- (2011) Rebekka Krumbach et al. EUROPEAN JOURNAL OF CANCER
- Predictive gene signatures for bevacizumab and cetuximab as well as cytotoxic agents
- (2011) Heinz-Herbert Fiebig et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
- (2011) Mark J. Anderton et al. TOXICOLOGIC PATHOLOGY
- PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data
- (2009) C. D. Greenman et al. BIOSTATISTICS
- Targeting transforming growth factor (TGF)-βRI inhibits activation of β1 integrin and blocks vascular invasion in hepatocellular carcinoma
- (2009) Emilia Fransvea et al. HEPATOLOGY
- Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells
- (2008) Emilia Fransvea et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started